This World Alzheimer’s Month, we honor those impacted by the disease. Alzheimer’s affects 55M+ people worldwide with no treatment to restore memory. At Spinogenix, we’re developing SPG302 to repair synapses and bring new hope. #AAIC #AlzheimersDisease spinogenix.com

Schizophrenia treatment has seen little change in 50+ years. New approaches like muscarinic-targeting drugs — and synaptic regeneration — could shift care from symptom management to true recovery. 📖 Read more: technologynetworks.com/tn/articles/sy…

Last week’s Harmony trial results brought mixed news for the Fragile X community. In this discussion, Dr. Stella Sarraf and Dr. Craig Erickson of Spinogenix share lessons learned and why they remain optimistic about SPG601. Watch the full conversation here👇

Spinogenix will be at at the NEALS Annual Meeting in Clearwater, FL (Oct 7–10) to share Phase 2a topline results on SPG302 in ALS. Excited to connect with the #ALSResearch community and explore new collaborations. #ALS #NEALS2025 #ClinicalResearch #Spinogenix #SPG302

Exciting progress from Spinogenix ahead of AAO: preclinical results show SPG302 protects retinal cells and preserves vision — highlighting synaptic regeneration as a new path for treating retinal disease. Read more: prnewswire.com/news-releases/…

Dr. Craig Erickson will present full Phase 2a results for SPG601 at AACAP 2025, highlighting improvements in adults with Fragile X Syndrome. He’ll also receive the George Tarjan Award for his work in developmental disabilities. Read more | spinogenix.com/spinogenix-to-…

Positive Phase 2a results for SPG302, our first-in-class regenerative ALS treatment, presented at NEALS. “SPG302 represents an important new approach to target synapse loss in ALS.” — Dr. Merit Cudkowicz 🔗 spinogenix.com/spinogenix-pre…

Spinogenix is pleased to share that the World Health Organization has approved #tazbentetol as the INN for our investigational synaptic regenerative therapy (formerly #SPG302), now in Phase 2 studies in Alzheimer’s, ALS, and schizophrenia. 🔗spinogenix.com/spinogenix-ann…

Encouraging results from our Phase 2a trial of Tazbentetol (formerly SPG302) in Alzheimer’s disease were presented at #CTAD2025. Data showed rapid cognitive gains, sustained improvement, strong safety, and EEG evidence of synaptic regeneration. 🔗 spinogenix.com/spinogenix-rep…

Last Friday marked an important milestone for our synaptic regeneration work in ALS. Professor Dominic Rowe presented Phase 2a results of Tazbentitol (formerly SPG302) at the 36th International Symposium on ALS/MND. Grateful to Prof. Rowe and all ALS participants.

Closing out 2025 grateful for meaningful progress at Spinogenix—Phase 2a results, regulatory milestones, and WHO approval of tazbentetol (SPG302) across ALS, Alzheimer’s, Fragile X syndrome, and schizophrenia. Thank you to the patients, families, and teams.

Spinogenix will participate in the Global BioInnovation Forum during the JP Morgan Healthcare Conference, taking place virtually on Jan 13, 2026. We look forward to joining a global conversation on the future of health. Thanks to FINN Partners, Gil Bashe, and 1BusinessWorld.

Dr. Craig Erickson joined Power To The Patients to discuss restoring the synapse as a new approach to treating complex brain disorders. Watch: youtube.com/watch?v=W1n23B… Listen: podcasts.apple.com/us/podcast/pow… #Spinogenix #Neuroscience #FragileX #ALS #Alzheimers #Schizophrenia

On Rare Disease Day, @Spinogenix stands with the ALS and Fragile X communities. Awareness is not enough. Patients deserve progress. We are advancing novel investigational therapies designed to restore synaptic function. Learn more: spinogenix.com #RareDiseaseDay

Grateful to FRAXA Research for supporting the PIs leading our Phase 2b trial of SPG601 in Fragile X syndrome. With no FDA-approved treatments, urgency matters. SPG601 has received FDA Fast Track and Orphan Drug Designations (FDA and EMA). 🔗spinogenix.com/press-release/…

Many neurological diseases look different on the surface. Beneath them, early synapse loss may be a shared thread. In The Scientist, Dr. Vanderklish discusses why restoring synaptic connections could reshape treatment development. Read more: the-scientist.com/regenerating-s…

Spinogenix has completed enrollment in its Phase 2 clinical trial evaluating tazbentetol for schizophrenia. Interim results will be presented by David Walling, PhD, at the Schizophrenia International Research Society Congress later this month. 🔗 spinogenix.com/press-release/…

Last week at SIRS 2026, Dr. David Walling presented interim Phase 2 data on tazbentetol (300mg, 6 weeks, n=16). Well tolerated with no severe AEs. PANSS: −11.9 vs −5.6 (Δ −6.3) Positive: +3.3 vs +0.1 (p=0.01) EEG signals support pharmacologic effect. spinogenix.com/press-release/…

SPG601 in Fragile X is now published in nature Scientific Reports. A Phase 2a study showed simultaneous improvement in EEG brain activity and cognition, a first in FXS research. Favorable safety, Fast Track status, and a registrational trial ahead. spinogenix.com/press-release/…

A milestone for the #FragileX community. We've announced CLARITY — our Phase 2b/3 trial of SPG601 in FXS. No approved treatments exist. The community has waited long enough. CLARITY is our commitment to change that. 🔗 spinogenix.com/press-release/…